Compugen Company Profile (NASDAQ:CGEN)

About Compugen (NASDAQ:CGEN)

Compugen logoCompugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CGEN
  • CUSIP: N/A
  • Web: www.cgen.com
Capitalization:
  • Market Cap: $196.86 million
  • Outstanding Shares: 51,131,000
Average Prices:
  • 50 Day Moving Avg: $3.56
  • 200 Day Moving Avg: $3.81
  • 52 Week Range: $2.60 - $6.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.70
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $123,000.00
  • Price / Sales: 1,600.44
  • Book Value: $0.92 per share
  • Price / Book: 4.18
Profitability:
  • EBITDA: ($33,140,000.00)
  • Return on Equity: -57.69%
  • Return on Assets: -50.83%
Debt:
  • Current Ratio: 9.40%
  • Quick Ratio: 9.40%
Misc:
  • Average Volume: 120,536 shs.
  • Beta: 0.68
  • Short Ratio: 13.46
 

Frequently Asked Questions for Compugen (NASDAQ:CGEN)

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. View Compugen's Earnings History.

When will Compugen make its next earnings announcement?

Compugen is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Compugen.

Where is Compugen's stock going? Where will Compugen's stock price be in 2017?

1 analysts have issued twelve-month price targets for Compugen's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Compugen's stock price to reach $14.00 in the next twelve months. View Analyst Ratings for Compugen.

What are analysts saying about Compugen stock?

Here are some recent quotes from research analysts about Compugen stock:

  • 1. According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (10/3/2017)
  • 2. FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:

  • Martin S. Gerstel, Chairman of the Board
  • Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director
  • Ari Krashin, Chief Financial Officer
  • Zurit Levine Ph.D., Vice President - Research and Discovery
  • John Hunter, Vice President - Antibody Research & Development
  • Dov Hershberg, Director
  • Michal Preminger Ph.D., Director
  • Yair Aharonowitz Ph.D., Independent External Director
  • Ruth Arnon, Independent Director
  • Arie Ovadia, Independent External Director

How do I buy Compugen stock?

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of Compugen stock can currently be purchased for approximately $3.85.


MarketBeat Community Rating for Compugen (NASDAQ CGEN)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  255
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Compugen (NASDAQ:CGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (263.64% upside)
Consensus Price Target History for Compugen (NASDAQ:CGEN)
Price Target History for Compugen (NASDAQ:CGEN)
Analysts' Ratings History for Compugen (NASDAQ:CGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017FBR & CoSet Price TargetBuy$14.00HighView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
2/11/2016Jefferies Group LLCReiterated RatingBuy$11.00 -> $9.00N/AView Rating Details
2/1/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Compugen (NASDAQ:CGEN)
Earnings by Quarter for Compugen (NASDAQ:CGEN)
Earnings History by Quarter for Compugen (NASDAQ CGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017        
8/2/20176/30/2017($0.17)($0.18)$0.21 millionViewListenView Earnings Details
5/9/20173/31/2017($0.18)($0.17)$0.06 millionViewListenView Earnings Details
2/15/2017Q416($0.18)($0.17)$0.13 million$0.05 millionViewListenView Earnings Details
11/7/2016Q316($0.14)($0.15)$0.41 million$0.07 millionViewN/AView Earnings Details
8/2/2016Q116($0.17)($0.13)$0.11 million$0.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.16)($0.17)$0.12 million$0.09 millionViewListenView Earnings Details
2/9/2016Q415($0.11)($0.01)$3.33 million$8.30 millionViewN/AView Earnings Details
11/3/2015Q315($0.15)($0.13)$0.92 million$0.23 millionViewN/AView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.58 million$0.22 millionViewN/AView Earnings Details
5/5/2015Q115($0.13)($0.12)$1.88 million$0.51 millionViewN/AView Earnings Details
2/10/2015Q414($0.08)($0.03)$3.70 million$6.60 millionViewN/AView Earnings Details
10/29/2014Q314($0.11)($0.11)$1.90 million$1.70 millionViewN/AView Earnings Details
8/6/2014Q214($0.10)($0.07)$1.85 million$2.00 millionViewN/AView Earnings Details
5/19/2014Q114($0.11)($0.04)$0.16 million$2.10 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)$0.13 million$1.80 millionViewN/AView Earnings Details
10/29/2013Q313($0.12)$0.11 million$1.60 millionViewN/AView Earnings Details
11/5/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Compugen (NASDAQ:CGEN)
2017 EPS Consensus Estimate: ($0.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.17)($0.18)
Q2 20172($0.17)($0.17)($0.17)
Q3 20172($0.19)($0.17)($0.18)
Q4 20172($0.18)($0.17)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Compugen (NASDAQ:CGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Compugen (NASDAQ:CGEN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Compugen (NASDAQ:CGEN)
Latest Headlines for Compugen (NASDAQ:CGEN)
Source:
DateHeadline
seekingalpha.com logoCompugen's CGEN-15032 shows potential as immuno-suppressive target in research study, shares ahead 8% premarket - Seeking Alpha
seekingalpha.com - October 11 at 6:39 PM
finance.yahoo.com logoCorporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032
finance.yahoo.com - October 11 at 6:39 PM
streetinsider.com logoCompugen (CGEN) Says New Immunomodulatory Target Demonstrates Potential for First-in-Class Cancer Therapy - StreetInsider.com
www.streetinsider.com - October 9 at 5:47 PM
finance.yahoo.com logoA New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy
finance.yahoo.com - October 9 at 5:47 PM
finance.yahoo.com logoFlexion Shares Continue Rise After FDA Approval -- Biotech Movers
finance.yahoo.com - October 9 at 5:47 PM
finance.yahoo.com logoCompugen Ltd (CGEN): How Does It Impact Your Portfolio?
finance.yahoo.com - October 2 at 4:28 PM
americanbankingnews.com logoFinancial Review: Incyte Corporation (INCY) versus Compugen (CGEN)
www.americanbankingnews.com - September 16 at 2:30 AM
finance.yahoo.com logoCompugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
finance.yahoo.com - August 7 at 5:32 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Compugen Ltd. (NASDAQ:CGEN) Reduced by Jefferies Group
www.americanbankingnews.com - August 4 at 8:30 AM
americanbankingnews.com logoCompugen Ltd. (CGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - August 3 at 8:08 PM
streetinsider.com logoCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board - StreetInsider.com
www.streetinsider.com - August 3 at 6:36 PM
seekingalpha.com logoCompugen's (CGEN) CEO Anat Cohen-Dayag on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 2 at 5:54 PM
streetinsider.com logoCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board
www.streetinsider.com - August 2 at 5:54 PM
finance.yahoo.com logoCompugen Reports Second Quarter 2017 Results
finance.yahoo.com - August 2 at 5:54 PM
finance.yahoo.com logoCompugen Welcomes Paul Sekhri as its New Chairman of the Board
finance.yahoo.com - August 2 at 5:54 PM
finance.yahoo.com logoCompugen reports 2Q loss
finance.yahoo.com - August 2 at 5:54 PM
americanbankingnews.com logo Brokerages Expect Compugen Ltd. (CGEN) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - July 28 at 10:24 PM
reuters.com logoBRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
www.reuters.com - July 28 at 2:38 AM
streetinsider.com logoCompugen (CGEN) Reprts Updates to Collaborative Activities with Bayer in Immuno-Oncology
www.streetinsider.com - July 28 at 2:38 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Boeing, AMD, Akamai, Corning - Nasdaq
www.nasdaq.com - July 27 at 9:37 PM
americanbankingnews.com logoCompugen Ltd. (CGEN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 27 at 9:59 AM
streetinsider.com logoCompugen (CGEN) Reprts Updates to Collaborative Activities with ... - StreetInsider.com
www.streetinsider.com - July 26 at 5:39 PM
finance.yahoo.com logoCompugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology
finance.yahoo.com - July 26 at 5:39 PM
streetinsider.com logoCompugen (CGEN) Receives US Patent for COM701 - StreetInsider.com
www.streetinsider.com - July 25 at 5:07 PM
finance.yahoo.com logoCompugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate
finance.yahoo.com - July 25 at 5:06 PM
finance.yahoo.com logoCompugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET
finance.yahoo.com - July 24 at 11:40 AM
americanbankingnews.com logo$210,000.00 in Sales Expected for Compugen Ltd. (CGEN) This Quarter
www.americanbankingnews.com - July 6 at 10:04 AM
americanbankingnews.com logoCompugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - July 4 at 6:20 PM
streetinsider.com logoCompugen (CGEN) Reports COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models at ... - StreetInsider.com
www.streetinsider.com - June 6 at 4:27 PM
seekingalpha.com logoCompugen provides update on COM701 and upcoming ... - Seeking Alpha
seekingalpha.com - May 31 at 9:31 PM
streetinsider.com logoCompugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.com
www.streetinsider.com - May 25 at 5:43 PM
streetinsider.com logoCompugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.com
www.streetinsider.com - May 25 at 5:43 PM
prnewswire.com logoCompugen Reports First Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 8:25 AM
prnewswire.com logoCompugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO - PR Newswire (press release)
www.prnewswire.com - May 6 at 6:40 AM
reuters.com logoBRIEF-Compugen ltd selects of com902 as lead clinical antibody candidate for immuno-oncology program
www.reuters.com - March 28 at 9:03 PM
streetinsider.com logoForm 6-K COMPUGEN LTD For: Mar 28 - StreetInsider.com
www.streetinsider.com - March 28 at 12:46 PM
streetinsider.com logoCompugen (CGEN) Announces Presentations of Summary Results of COM701 at AACR - StreetInsider.com
www.streetinsider.com - March 3 at 4:15 PM
prnewswire.com logoCompugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery ... - PR Newswire (press release)
www.prnewswire.com - March 2 at 7:12 AM
us.rd.yahoo.com logoCompugen Reports Fourth Quarter and Calendar Year 2016 Results
us.rd.yahoo.com - February 16 at 9:30 AM
nasdaq.com logoFNY Managed Accounts LLC Buys Tesla, St Jude Medical, SPDR S&P 500, Sells LinkedIn, NXP ...
www.nasdaq.com - February 9 at 9:38 PM
streetinsider.com logoCompugen (CGEN) Says CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity
www.streetinsider.com - January 4 at 5:18 PM
reuters.com logoBRIEF-Compugen says disclosed animal model results demonstrating restoration of immune tolerance by cgen-15001
www.reuters.com - January 4 at 5:18 PM
us.rd.yahoo.com logoCompugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity
us.rd.yahoo.com - January 4 at 5:18 PM
nasdaq.com logoWhat Makes Compugen Ltd. (CGEN) a Strong Sell? - Nasdaq
www.nasdaq.com - December 22 at 4:24 PM
prnewswire.com logoCompugen Announces Key Highlights from R&D Day - PR Newswire - PR Newswire (press release)
www.prnewswire.com - December 8 at 5:03 PM
prnewswire.com logoCompugen Discloses its Cancer Immunotherapy Program Targeting ... - PR Newswire (press release)
www.prnewswire.com - December 8 at 5:03 PM
seekingalpha.com logoCompugen announces key highlights from R&D day - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 8 at 5:03 PM
us.rd.yahoo.com logoCompugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint
us.rd.yahoo.com - December 7 at 4:54 PM
us.rd.yahoo.com logo7:26 am Compugen discusses data demonstrating that the CGEN-15029/PVRIG immune checkpoint represents a new inhibitory component of the known TIGIT axis at recent SITC Annual Meeting
us.rd.yahoo.com - December 7 at 4:54 PM

Social

Chart

Compugen (CGEN) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.